Samsung Biologics unveils new CDO platforms at 2024 BPI in Boston

Samsung Biologics booth at the 2024 BioProcess International exhibition. (Samsung Biologics)

Samsung Biologics announced the launch of two new contract development (CDO) platforms on Wednesday at the 2024 BioProcess International (BPI) Conference & Exhibition in Boston. With these additions, the company now offers a total of nine CDO platforms and services.

The annual BPI conference is a global event where companies showcase the latest technologies in biopharmaceutical development, production, and analysis. The 2024 edition, which runs through Thursday, is expected to attract over 3,200 experts and feature more than 220 companies with exhibition booths.

Samsung Biologics has participated in the BPI for seven consecutive years, since entering the CDO business in 2018, and presented its dedicated booth again in 2024.

The newly introduced platforms, S-AfuCHO™ and S-Opticharge™, are designed to enhance the effectiveness of antibodies in cancer treatment and enable the production of high-quality proteins. S-AfuCHO™ is an afucosylated cell line platform that refers to the removal of the sugar molecule “fucose.” This platform allows for the production of antibodies with enhanced antibody-dependent cellular cytotoxicity (ADCC), a key indicator of cancer-fighting potential.

According to Samsung Biologics, the S-AfuCHO™ platform has improved the anti-cancer efficacy of antibodies by 14 times compared to previous cell lines.